舒尼替尼与Combretastatin A-4联合用药体外抑制人胃癌SGC-7901细胞增殖作用研究

Synergistic Anti-tumor activity of Sunitinib Combined with Combretastatin A-4 in SGC-7901 Cells by Apoptosis

摘要: 目的对舒尼替尼与Combretastatin A-4(CA-4)联合用药的抗肿瘤活性进行研究。方法 SRB法测定比较舒尼替尼、CA-4及联合用药对人胃癌SGC-7901细胞增殖抑制作用。PI染色法、DAPI染色法及Western blot法检测舒尼替尼联合应用CA-4诱导人胃癌SGC-7901细胞凋亡作用。结果联用舒尼替尼和CA-4在体外能协同抑制人胃癌SGC-7901细胞的增殖。舒尼替尼联用CA-4能够诱导SGC-7901肿瘤细胞凋亡，并且伴随着caspase-3的激活和PARP的裂解。结论舒尼替尼与CA-4联合用药在体外能协同诱导人胃癌SGC-7901肿瘤细胞增殖。

Abstract: OBJECTIVE To study the anti-cancer activity of the combination of CA-4 and sunitinib. METHODS The anti-proliferation activity of CA-4 and sunitinib were analyzed by SRB, apoptosis was detected by PI, DAPI and Western blot analysis. RESULTS The present study indicated that the combination of sunitinib and CA-4 exerted synergistic anti-proliferative effects against human gastric cancer cells SGC-7901 in vitro. The enhanced apoptosis induced by sunitinib plus CA-4 was accompanied by the greater extent of caspases-3 activation and PARP cleavage in SGC-7901 cells. CONCLUSION These findings build the rationale for further clinical development of sunitinib and CA-4 against gastric cancer (SGC-7901).